ADCs and BIOSIMILARS: The development towards a new generation of targeted therapies

Aug 25, 2017

Antibodies-based therapeutics are perhaps the most successful and versatile drug approach developed in the last 30 years. They not only have found application as vaccines and drug carriers but have also been applied to analytical methods such as ELISA (Enzyme-linked Immunosorbent Assay), Wester blotting and flow cytometry. The discovery of the smallpox vaccine by Jenner in the late 1700s certainly represents the paradigm shift for the most disparate applications of antibodies currently available in the biomedical market. Antibodies have evolved considerably from early stages and now are developed as the new generation – called Biobetter – which aim to minimise ...

Read More

Oxford Genetics Secures £7.5 Million Investment

Aug 22, 2017

21st August 2017, Oxford – Oxford Genetics, a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery, has announced a £7.5 million investment into its operations in the US and the UK by Mercia Technologies PLC, an existing investor, and Invesco Perpetual. This investment will fund a new office in Boston, US and a 6,000-sq. ft. extension of its UK facility at the Oxford Science Park by November 2017. The extension will include state-of-the-art cell line engineering capabilities, viral vector production and purification suites, high-throughput robotic screening systems and process development facilities. The company also plans to invest ...

Read More

New gas ramping function enables world’s first in vitro reproduction of ischaemia/reperfusion conditions in a microplate reader

Aug 15, 2017

BMG LABTECH reports successful development of new technology within the MetaCell-TM project Ortenberg, Germany (August 2017) – BMG LABTECH developed a new gas ramping function that can fully manipulate the environment within a microplate reader, by mimicking in vitro hypoxia and ischaemia/reperfusion. Equipped with this unique feature, the CLARIOstar® with Atmospheric Control Unit (ACU) is the first plate reader that is able to rapidly return to physiological gas conditions upon active modification of oxygen (02) and carbon dioxide (CO2) tensions within the reader, reproducing disease-specific settings in live cell-based assays. The use of conditions that resemble as close as possible ...

Read More

Envigo launches R2G2 double knockout mouse model

Apr 5, 2017

Unique mixed background mouse enables researchers to examine effects of a wider range of radiation dosages  Envigo announced today it will launch the “R2G2” mouse at the American Association for Cancer Research (AACR) annual meeting in Washington DC, April 1-5, 2017. The R2G2, a Rag2/IL2RG double knockout model, was created by backcrossing the common gamma chain gene mutation (IL2RG) on to a unique C57BL/6 and 129 mixed background mouse with a mutation in the recombination activating gene 2 (Rag2). The R2G2 mouse addresses common challenges that researchers experience with current models used in oncology, immuno-oncology and infectious disease research. The ...

Read More

Aesica adds development capability at Queenborough with opening of new purpose built facility – Product life cycle services expanded including for high potent and controlled drugs

Apr 11, 2016

5 April 2016: Aesica Pharmaceuticals, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced the doubling of its development capacity – manufacturing multiple drug products up to  Phase III clinical trials at Queenborough. With the addition of the new capabilities, Aesica can now develop and manufacture a customer product from early formulation development through clinical manufacture and into commercialisation – covering all aspects of product life cycle on the one site. This process will now be a seamless end-to-end service offering for the customer The company’s high potent and controlled drugs service offering has been significantly expanded ...

Read More